Antiphospholipid Syndrome Related Thrombosis: Understanding The Disease Pathogenic Mechanisms Is The Key To Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$607,497.00
Summary
Patients with the Antiphospholipid Syndrome develop thrombosis at a young age. It requires long-term treatment with blood thinning medications, which have risks of severe bleeding. Methods are needed to decide which patients require long term treatment, avoiding unnecessary treatment in low risk patients. Such methods do not currently exist. In this study we explore how useful two novel assays developed by us are in identifying which of these patients are at high risk of thrombosis.
Waxing And Waning Of Asthma During Transition From The Teens To Adulthood: Identification Of Immunophenotypic Markers To Predict Disease Trajectory And Guide Development Of Treatment Strategies To Prevent Progression To Chronicity
Funder
National Health and Medical Research Council
Funding Amount
$736,166.00
Summary
The project will seek to identify biomarkers in teenage/young adult asthmatics that can distinguish between those who are "growing out" of the disease, versus those who are progressing towards chronic severe asthma. This knowledge will inform the development of more effective treatment programs for this age group.
Characterising The Tumour Suppressive Function Of Myoepithelial Cell Stefin A In Ductal Carcinoma In Situ
Funder
National Health and Medical Research Council
Funding Amount
$474,840.00
Summary
Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer, whereby the tumour cells remain restrained by myoepithelial cells that surround breast ducts. Predicting which cases of DCIS will later develop invasive cancer is difficult, meaning that the majority of patients have treatment. Stefin A is a protease inhibitor in myoepithelial cells shown to block cancer invasion and we aim to test the function of this protein in DCIS and its potential as a prognostic marker.
PRECISION: Personalised Risk Evaluation In DCIS, International
Funder
National Health and Medical Research Council
Funding Amount
$1,392,930.00
Summary
Ductal carcinoma in situ (DCIS) of the breast is a common diagnosis with problematic clinical management. This study brings together an international consortium to identify and validate clinical biomarkers of recurrence.
Novel Molecular Markers Of Lung Cancer Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$824,765.00
Summary
Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomar ....Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomarkers of risk and survival.Read moreRead less
Understanding Sensitivity And Resistance To Trastuzumab And Lapatinib In HER2 Overexpressing Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$414,056.00
Summary
Previously, women diagnosed with a breast cancer that overexpressed the HER2 protein had a very high risk of dying. Trastuzumab, a treatment targeted at this protein, has been an extremely effective treatment. Currently there are new anti-HER2 drugs available, which will likely to be used in combination with trastuzumab. We will be investigating biological markers of resistance and sensitivity to these drugs and combinations in order to try and understand who needs which drug and/ or combination ....Previously, women diagnosed with a breast cancer that overexpressed the HER2 protein had a very high risk of dying. Trastuzumab, a treatment targeted at this protein, has been an extremely effective treatment. Currently there are new anti-HER2 drugs available, which will likely to be used in combination with trastuzumab. We will be investigating biological markers of resistance and sensitivity to these drugs and combinations in order to try and understand who needs which drug and/ or combinations.Read moreRead less
Bronchiectasis And Infection With The Human T-lymphotropic Virus 1 Among Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$849,674.00
Summary
The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis ....The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis of HTLV infection.Read moreRead less
Tumours secrete factors which are contained in specific structures called exosomes, and are used to prepare other organs of the body for subsequently incoming tumour cells, thereby facilitating the often mortal spread of the cancer. This project will investigate the way exosomes alter organs before tumour cells arrive, the composition of these exosomes in lung cancer patients and if they are novel markers for diseases progression as well as therapeutic intervention.
Genomic Medicine: Predictors Of Refractory Ulcerative Colitis And Its Response To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$879,048.00
Summary
Ulcerative colitis (UC) is a major form of inflammatory bowel disease, affecting over 35,000 Australians. Symptoms include bleeding from the anus, tummy pain, and diarrhoea. There is a 1 in 4 risk of needing major surgery for UC. Our study will use current genetic techniques to classify patients according to the severity of their colitis, and their response to treatments. This will allow clinicians to personalize medical treatment far more effectively from the outset of a patients’ disease.
A Prospective Clinical Trial To Establish The Significance Of Interim FDG And FLT PET/CT Scans As Biomarkers Of Patient Prognosis And Individualised Radiation Therapy In Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$532,902.00
Summary
Positron Emission Tomography (PET)/Computed Tomography (CT) scanners pinpoint the location of cancer cells in people prior to and after treatment. This innovative study will use during treatment PET/CT scans to establish the response of lung tumours to radiation therapy (RT). We will use these scans to simulate the delivery of highly targeted, individualised RT and to predict patient prognosis, with the ultimate aim of increasing survival and minimising side effects in patients with lung cancer